FDA Scrutiny Intensifies: Aurobindo Pharma Faces Multiple Regulatory Challenges

Aurobindo Pharma is grappling with heightened regulatory scrutiny as its facilities face multiple US FDA actions. The company's Unit III formulation manufacturing facility in Telangana received an "Official Action Indicated" (OAI) classification following a January-February 2024 inspection. Additionally, the FDA concluded a pre-approval inspection at Eugia Steriles in Andhra Pradesh with five procedural observations in February 2025. These developments follow earlier FDA concerns, including a December 2023 inspection of Eugia US that resulted in 10 observations. Aurobindo Pharma remains committed to addressing these issues and enhancing compliance, but the regulatory challenges may impact future approvals and operations.
Sources: Aurobindo Pharma Limited, Bajaj Broking, FiercePharma